NASDAQ:ALEC - Alector Stock Price, Forecast & News

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALEC shares have decreased by 8.7% and is now trading at $22.76. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Alector.

Alector Inc (NASDAQ:ALEC) announced its quarterly earnings data on Tuesday, March, 24th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.03. The firm had revenue of $6 million for the quarter, compared to analyst estimates of $9.60 million. Alector had a negative net margin of 496.65% and a negative return on equity of 45.56%. View Alector's earnings history.

5 brokers have issued 12 month target prices for Alector's stock. Their forecasts range from $28.00 to $28.00. On average, they anticipate Alector's share price to reach $28.00 in the next year. This suggests a possible upside of 23.0% from the stock's current price. View analysts' price targets for Alector.

Media stories about ALEC stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alector earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAlector.

Some companies that are related to Alector include BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT), Audentes Therapeutics (BOLD), Crispr Therapeutics (CRSP), bluebird bio (BLUE), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Cisco Systems (CSCO), Alibaba Group (BABA), Advanced Micro Devices (AMD), AT&T (T), Verizon Communications (VZ), Johnson & Johnson (JNJ), Gossamer Bio (GOSS) and Kaleido Biosciences (KLDO).

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (3.42%), Casdin Capital LLC (1.56%), State Street Corp (1.51%), Franklin Resources Inc. (1.15%), Franklin Resources Inc. (1.15%) and Marshall Wace North America L.P. (1.01%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Bamco Inc. NY, Spark Investment Management LLC, UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, and Sabah Oney. View insider buying and selling activity for Alector.

ALEC stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Pictet Asset Management Ltd., State Street Corp, FMR LLC, Casdin Capital LLC, Franklin Resources Inc., Franklin Resources Inc., and Oppenheimer & Co. Inc.. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc. View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $22.76.

Alector has a market capitalization of $1.79 billion and generates $21.22 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe. View additional information about Alector.

The official website for Alector is http://www.alector.com/.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]